Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.
Georgie MathewAditi SinhaAijaz AhmedNeetu GrewalPriyanka KhandelwalPankaj HariArvind BaggaPublished in: Pediatric nephrology (Berlin, Germany) (2022)
Therapy with rituximab was not shown to be non-inferior to 12-months treatment with tacrolimus in maintaining remission in patients with difficult-to-treat steroid-sensitive nephrotic syndrome. Frequent relapses were more common with rituximab. While effective, both agents require close monitoring for adverse events. A higher resolution version of the Graphical abstract is available as Supplementary information.
Keyphrases
- diffuse large b cell lymphoma
- randomized controlled trial
- chronic lymphocytic leukemia
- hodgkin lymphoma
- study protocol
- disease activity
- clinical trial
- stem cells
- combination therapy
- health information
- systemic lupus erythematosus
- single molecule
- rheumatoid arthritis
- bone marrow
- replacement therapy
- psychometric properties